Acrivon Therapeutics (ACRV) Stock
Small biotech developing treatments for infections and skin conditions. Here's the price, business snapshot, and what's worth knowing about Acrivon Therapeutics in July 2026.
Acrivon Therapeutics (ACRV) is a small-cap, clinical-stage biotechnology company focused on developing therapies in the anti‑infective and dermatology area. With a market capitalisation of about $64.17 million, the company is primarily valuation-driven by clinical progress, partnerships and regulatory milestones rather than steady revenues. Investors should expect binary events — clinical readouts, regulatory interactions or licensing deals — that can materially move the share price. Typical considerations include limited cash runway at smaller market caps, potential dilution from future financings, and long development timelines intrinsic to biotech. Due diligence should focus on the company’s pipeline, trial design and timelines, management experience, and cash position. This summary is general educational information and not personalised investment advice; biotech stocks can be volatile and investors may wish to consider how such high‑risk, high‑reward exposures fit with their broader portfolio and risk tolerance.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Acrivon Therapeutics' stock, anticipating it could rise significantly.
Financial Health
ACRIVON is showing solid financial performance with healthy cash flow and book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring ACRV
Precision Oncology Stocks: Could This Theme Gain Momentum?
Revolution Medicines recently reported stellar Phase 3 trial results for its pancreatic cancer drug, sending its stock soaring and validating novel targeted therapies. This breakthrough creates a compelling investment opportunity across the broader oncology sector, particularly for biotechnology firms specializing in genetic mutations and precision medicine.
Published: 14 April 2026
Explore BasketBiotech Buyout Candidates (Post-Merck Acquisition)
Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.
Published: 17 November 2025
Explore BasketClinical Trial Tech: Growth vs Competition Risks
Thermo Fisher's multi-billion dollar acquisition of Clario, a clinical trial data company, signals a major industry shift towards digital solutions. This creates a compelling investment case for companies specializing in the software and data analytics that power modern drug development.
Published: 29 October 2025
Explore BasketOncology Stocks: Could Combination Therapies Drive Growth?
Astellas and Pfizer's successful trial for a new combination bladder cancer therapy highlights a significant advancement in oncology. This breakthrough signals a promising investment opportunity in the broader field of innovative cancer treatments, especially among companies developing combination therapies and targeted drugs.
Published: 19 October 2025
Explore BasketAlternative Cancer Therapies Focus Shifts 2025
The FDA's new boxed warning for Johnson & Johnson and Legend Biotech's cancer drug highlights potential safety issues in CAR-T therapies. This could shift focus to companies developing alternative and potentially safer oncology treatments.
Published: 13 October 2025
Explore BasketFDA Cancer Warning: Beyond the Treatment Headlines
The FDA's new boxed warning for a major cancer therapy from Johnson & Johnson and Legend Biotech highlights the serious side effects of advanced treatments. This focus creates an investment opportunity in companies that develop drugs and therapies to help manage these adverse reactions, improving patient quality of life.
Published: 12 October 2025
Explore BasketCancer Drug Safety: Could Warnings Create Opportunities?
The FDA's decision to add its strongest safety warning to a key cancer therapy from Johnson & Johnson and Legend Biotech underscores the inherent risks of powerful new treatments. This regulatory action could boost companies developing safer alternative cancer therapies, creating a new investment opportunity in the biotech sector.
Published: 11 October 2025
Explore BasketPharma M&A Targets: Biotech Stocks to Watch 2025
AbbVie is spending $2.7 billion on external R&D, highlighting a major industry trend of large pharmaceutical companies acquiring innovation. This creates a potential opportunity among the smaller biotech firms that are becoming prime acquisition targets.
Published: 5 October 2025
Explore BasketInjectable Drug Innovation Opportunities 2025
The FDA's approval of an at-home injectable version of Eisai and Biogen's Alzheimer's drug, Leqembi, simplifies treatment for patients and caregivers. This development highlights a growing trend toward patient-centric care, creating investment opportunities in companies that specialize in innovative drug delivery systems and at-home therapeutic technologies.
Published: 31 August 2025
Explore BasketTargeting Superbugs: The Next Wave Of Antibiotics
GSK's new antibiotic for gonorrhea has received priority review from the FDA, underscoring the urgent need for new antimicrobial treatments. This event signals a potential resurgence in the market for companies developing novel antibiotics to address drug-resistant infections.
Published: 11 August 2025
Explore BasketChina's Biopharma Innovators: The Next Global Partnership Wave
Following GSK's major licensing deal with China's Jiangsu Hengrui, a new investment theme is emerging around Chinese pharmaceutical innovators. This theme focuses on other Chinese biopharma companies that are likely to attract similar global partnerships, driving value through their advanced drug development pipelines.
Published: 28 July 2025
Explore BasketPharma's Next Big Deal
This carefully curated group of stocks features promising biotech companies with valuable drug pipelines. These smaller firms could become the next targets for lucrative partnerships or acquisitions by pharmaceutical giants, similar to Glenmark's recent $2 billion deal with AbbVie.
Published: 11 July 2025
Explore BasketAge-Reversal Biotech
Invest in pioneering companies that are redefining aging as a treatable condition. These carefully selected biotechs are developing groundbreaking therapies to extend healthy lifespans and potentially reverse cellular damage, creating an entirely new frontier in medicine.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical catalysts ahead
Trial readouts and regulatory milestones can create sharp share moves; these events are important to follow, though outcomes are uncertain.
Innovation in antimicrobials
If the pipeline shows efficacy, there is commercial potential in anti‑infective and dermatology markets; remember development is lengthy and risky.
Small‑cap dynamics
Lower market cap may mean limited liquidity and higher volatility, and the company may need additional funding, which can dilute shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.